Short-course fluoroquinolone therapy in exacerbations of chronic bronchitis and COPD

Respiratory Medicine

Volumn 104, Issue 10, 2010, Pages 1396-1403

  Anzueto, Antonio ^a   Miravitlles, Marc ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

AECB; Chronic bronchitis; COPD; Duration of therapy; Fluoroquinolones; Short course therapy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN;

ANTIMICROBIAL THERAPY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONVALESCENCE; DISEASE EXACERBATION; DRUG MEGADOSE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BRONCHITIS, CHRONIC; DISEASE PROGRESSION; FLUOROQUINOLONES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE;

EID: 77956338213     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.05.018     Document Type: Review

References (49)

1. M.S. Balter, J. La Forge, D.E. Low, L. Mandell, R.F. Grossman the Chronic Bronchitis Working Group on behalf of the Canadian Thoracic Society and the Canadian Infectious Disease Society Canadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summary Can Respir J 10 2003 248 258
2. G.C. Donaldson, T.A.R. Seemungal, A. Bhowmik, and J.A. Wedzicha Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 2002 847 852
3. J.J. Soler-Cataluña, M.A. Martinez-Gracía, P. Roman Sánchez, E. Salcedo, M. Navarro, and R. Ochando Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 2005 925 931
4. M. Miravitlles, M. Ferrer, A. Pont, R. Zalacain, J.L. Alvarez-Sala, and F. Masa Effect of exacerbations impair quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow-up study Thorax 59 2004 387 395
5. M. Miravitlles, A. Anzueto, D. Legnani, L. Forstmeier, and M. Fargel Patient's perception of exacerbations of COPD - the PERCEIVE study Respir Med 101 2007 453 460
6. A. Anzueto, S. Sethi, and F.J. Martinez Exacerbations of chronic obstructive pulmonary disease Proc Am Thorac Soc 4 2007 554 564
7. N.R. Anthonisen, J. Manfreda, C.P.W. Warren, E.S. Hershfield, G.K.M. Harding, and N.A. Nelson Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease Ann Intern Med 106 1987 196 204
8. M. Miravitlles, C. Murio, G. Tirado-Conde, G. Levy, H. Muellerova, and J.B. Soriano Geographic differences in clinical characteristics and management of COPD: the EPOCA study Int J Chron Obstruc Pulmon Dis 3 2008 803 814
9. S. Sethi Infectious etiology of acute exacerbations of chronic bronchitis Chest 17 2000 380S 385S
10. A. Papi, C.N.M. Bellettato, F. Braccioni, M. Romangoli, P. Casolari, and G. Caramori Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations Am J Respir Crit Care Med 173 2006 1114 1121
11. M. Miravitlles, C. Espinosa, E. Fernandez-Laso, J.A. Martos, J.A. Maldonado, and M. Gallego Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD Chest 116 1999 40 46
12. R.A. Stockley, C. O'Brien, A. Pye, and S.L. Hill Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD Chest 117 2000 1638 1645
13. J. Eller, A. Ede, T. Schaberg, M.S. Niederman, H. Mauch, and H. Lode Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function Chest 113 1998 1542 1548
14. T.A.R. Seemungal, R. Harpe-Owen, A. Bhowmik, D.J. Jeffries, and J.A. Wedzicha Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease Eur Respir J 16 2000 677 683
15. T.A.R. Seemungal, G.C. Donaldson, A. Bhowmik, D.J. Jeffries, and J.A. Wedzicha Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 1608 1613
16. V. Snow, S. Lascher, C. Mottur-Pilson for the Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American College of Physicians-American Society of Internal Medicine Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease Ann Intern Med 134 2001 595 599
17. S.G. Adams, J. Melo, M. Luther, and A. Anzueto Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD Chest 117 2000 1345 1352
18. M. Miravitlles Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis 1 2007 61 76
19. D.E. O'Donnell, S. Aaron, J. Bourbeau, P. Hernandez, D.D. Marciniuk, and M. Balter Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update Can Respir J 14 Suppl. B 2007 5B 32B
20. M. Miravitlles, E. Monso, J. Mensa, J. Aguarón Pérez, J. Barberán, and M. Bárcena Caamaño Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement Arch Bronconeumol 44 2008 100 108
21. M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, and A. Ortqvist Guidelines for the management of adult lower respiratory tract infections Eur Respir J 26 2005 1138 1180
22. F.J. Martinez, and A. Anzueto Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis Am J Med 118 7A 2005 39S 44S
23. C. Garcia-Vidal, P. Almagro, V. Romani, M. Rodriguez-Carballeira, and E. Cuchi Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Eur Respir J 34 5 2009 1072 1078
24. T.F. Murphy, A.L. Brauer, K. Eschberger, P. Lobbins, L. Grove, and X. Cai Pseudomonas aeruginosa in chronic obstructive pulmonary disease Am J Respir Crit Care Med 177 2008 853 860
25. A. Obaji, and S. Sethi Acute exacerbations of chronic bronchitis. What role for the new fluoroquinolones? Drugs Aging 18 2001 1 11
26. M.E. Falagas, S.G. Avgeri, D.K. Matthaiou, and G. Dimopoulos Siempos II. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis J Antimicrob Chemother 62 2008 442 450
27. S. Chodosh, C.A. Deabate, D. Haverstock, L. Aneiro, and D. Church Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis Respir Med 94 2000 18 27
28. M. Miravitlles, and A. Anzueto Moxifloxacin: a respiratory fluoroquinolone Expert Opin Pharmacother 9 2008 1755 1772
29. C. Grassi, L. Casali, E. Curti, M. Tellarini, C. Lazzaro, G. Schito on behalf of the SMART Study Group Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB) J Chemother 14 2002 597 608
30. R.F. Grossman, M.E. Ambrusz, A.C. Fisher, M.M. Khashab, and J.B. Kahn Levofloxacin 750 mg QD for five days versus amoxicillin/clavulanate 875 mg/125 mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis: a post hoc analysis of data from severely ill patients Clin Ther 28 2006 1175 1180
31. S. Spencer, and P.W. Jones Time course of recovery of health status following an infective exacerbation of chronic bronchitis Thorax 58 2003 589 593
32. R. Wilson, L. Allegra, G. Huchon, J.-L. Izquierdo, P. Jones, and T. Schaberg Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis Chest 125 2004 953 964
33. J. Chastre, M. Wolff, J.Y. Fagon, S. Chevret, F. Thomas, D. Wermert for the PneumA Trial Group Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial JAMA 290 2003 2588 2598
34. R. El Moussaoui, B.M. Roede, P. Speelman, P. Bresser, J.M. Prins, and P.M.M. Bossuyt Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies Thorax 63 2008 415 422
35. S. Sethi, J. Breton, and B. Wynne Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis Antimicrobial Agents Chemother 49 2005 153 160
36. M. Gotfried, G. Notario, J. Spiller, R. Palmer, and T. Busman Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis Curr Med Res Opin 21 2005 245 254
37. R.G. Masterton, and C.J. Burley Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis Int J Antimicrob Agents 18 2001 503 512
38. F.J. Martinez, R.F. Grossman, N. Zadeikis, A.C. Fisher, K. Walker, and M.E. Ambruzs Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg Eur Respir J 25 2005 1001 1010
39. J. Urueta-Robledo, H. Ariza, J.R. Jardim, A. Caballero, A. Garcia-Calderon, C.F. Amabile-Cuevas the MOX-CB Study Group Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort Respir Med 100 2006 1504 1511
40. I. Starakis, C.A. Gogos, and H. Bassaris Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis Int J Antimicrob Agents 23 2004 129 137
41. M. Zervos, F.J. Martinez, G.W. Amsden, C.D. Rothermel, and G. Treadway Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis Int J Antimicrob Agents 29 2007 56 61
42. R. Wilson, P. Jones, T. Schaberg, P. Arvis, I. Duprat-Lomon, P.P. Sagnier for the MOSAIC Study Group Antibiotic treatment and factors influencing short and long-term outcomes of acute exacerbations of chronic bronchitis Thorax 61 2006 337 342
43. S. Sethi, C. Fogarty, and A. Fulambarker A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis Respir Med 98 2004 697 707
44. R. Wilson, J.J. Schentag, P. Ball, L. Mandell for the 068 Study Group A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes Clin Ther 24 2002 639 652
45. T. File, B. Schlemmer, J. Garau, H. Lode, S. Lynch, C. Young the 070 Clinical Study Group Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis J Chemother 12 2000 314 325
46. M. Miravitlles, R. Zalacain, C. Murio, M. Ferrer, J.L. Alvarez-Sala, and J.F. Masa Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials Clin Drug Investig 23 2003 439 450
47. M. Miravitlles, C. Llor, K. Naberan, J.M. Cots, J. Molina for the EFEMAP Study Group Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease Respir Med 99 2005 955 965
48. T. Schaberg, M. Möller, T. File, K. Stauch, and H. Landen Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides Clin Drug Investig 26 2006 733 744
49. Marketing authorization application withdrawn for Factive (gemifloxacin) http://www.nelm.nhs.uk/en/NeLM-Area/News/2009 - June/24/Marketing-authorisation- application-withdrawn-for-Factive-gemifloxacin-/ Available at:Accessed 5.02.10